O	0	12	Introduction	Introduction	NN	B-NP

B-Tissue	13	20	Adipose	Adipose	NN	B-NP
I-Tissue	21	27	tissue	tissue	NN	I-NP
O	27	28	,	,	,	O
O	29	33	once	once	RB	B-ADVP
O	34	40	viewed	view	VBN	B-VP
O	41	43	as	as	IN	B-PP
O	44	50	simply	simply	RB	B-NP
O	51	52	a	a	DT	I-NP
O	53	60	storage	storage	NN	I-NP
O	61	64	and	and	CC	I-NP
O	65	72	release	release	NN	I-NP
O	73	78	depot	depot	NN	I-NP
O	79	82	for	for	IN	B-PP
O	83	89	lipids	lipid	NNS	B-NP
O	89	90	,	,	,	O
O	91	93	is	be	VBZ	B-VP
O	94	97	now	now	RB	I-VP
O	98	108	considered	consider	VBN	I-VP
O	109	111	an	an	DT	B-NP
B-Tissue	112	121	endocrine	endocrine	JJ	I-NP
I-Tissue	122	128	tissue	tissue	NN	I-NP
O	129	130	[	[	(	O
O	130	131	1	1	CD	B-NP
O	131	132	,	,	,	I-NP
O	132	133	2	2	CD	I-NP
O	133	134	]	]	)	O
O	135	139	that	that	WDT	B-NP
O	140	148	secretes	secrete	VBZ	B-VP
O	149	156	various	various	JJ	B-NP
O	157	167	substances	substance	NNS	I-NP
O	168	169	(	(	(	O
O	169	179	adipokines	adipokine	NNS	B-NP
O	179	180	)	)	)	O
O	180	181	,	,	,	O
O	182	191	including	include	VBG	B-PP
O	192	197	tumor	tumor	NN	B-NP
O	198	206	necrosis	necrosis	NN	I-NP
O	207	213	factor	factor	NN	I-NP
O	213	214	-	-	HYPH	O
O	214	219	alpha	alpha	SYM	B-NP
O	220	221	(	(	(	O
O	221	224	TNF	TNF	NN	B-NP
O	224	225	-	-	HYPH	O
O	225	230	alpha	alpha	SYM	B-NP
O	230	231	)	)	)	O
O	231	232	,	,	,	O
O	233	244	interleukin	interleukin	NN	B-NP
O	245	246	(	(	(	O
O	246	248	IL	IL	NN	B-NP
O	248	249	)	)	)	O
O	249	250	-	-	HYPH	B-NP
O	250	251	6	6	CD	I-NP
O	251	252	,	,	,	O
O	253	259	leptin	leptin	NN	B-NP
O	259	260	,	,	,	O
O	261	272	adiponectin	adiponectin	NN	B-NP
O	272	273	,	,	,	O
O	274	282	resistin	resistin	NN	B-NP
O	282	283	,	,	,	O
O	284	292	visfatin	visfatin	NN	B-NP
O	292	293	,	,	,	O
O	294	297	and	and	CC	O
O	298	306	omenetin	omenetin	NN	B-NP
O	307	308	[	[	(	B-NP
O	308	309	3	3	CD	I-NP
O	309	310	,	,	,	I-NP
O	310	311	4	4	CD	I-NP
O	311	312	]	]	)	O
O	312	313	.	.	.	O

O	314	319	Among	Among	IN	B-PP
O	320	325	these	these	DT	B-NP
O	326	336	adipokines	adipokine	NNS	I-NP
O	336	337	,	,	,	O
O	338	342	much	much	JJ	B-NP
O	343	352	attention	attention	NN	I-NP
O	353	356	has	have	VBZ	B-VP
O	357	361	been	be	VBN	I-VP
O	362	366	paid	pay	VBN	I-VP
O	367	369	to	to	TO	B-PP
O	370	381	adiponectin	adiponectin	NN	B-NP
O	381	382	'	'	POS	B-NP
O	382	383	s	s	NN	I-NP
O	384	396	relationship	relationship	NN	I-NP
O	397	401	with	with	IN	B-PP
O	402	409	insulin	insulin	NN	B-NP
O	410	421	sensitivity	sensitivity	NN	I-NP
O	422	425	and	and	CC	O
O	426	433	glucose	glucose	NN	B-NP
O	434	437	and	and	CC	I-NP
O	438	443	lipid	lipid	NN	I-NP
O	444	454	metabolism	metabolism	NN	I-NP
O	455	457	in	in	IN	B-PP
O	458	461	the	the	DT	B-NP
O	462	466	past	past	JJ	I-NP
O	467	469	10	10	CD	I-NP
O	470	475	years	year	NNS	I-NP
O	475	476	.	.	.	O

O	477	479	In	In	IN	B-PP
O	480	488	addition	addition	NN	B-NP
O	488	489	,	,	,	O
O	490	501	adiponectin	adiponectin	NN	B-NP
O	502	504	is	be	VBZ	B-VP
O	505	510	known	know	VBN	I-VP
O	511	513	to	to	TO	I-VP
O	514	521	exhibit	exhibit	VB	I-VP
O	522	528	potent	potent	JJ	B-NP
O	529	533	anti	anti	AFX	I-NP
O	533	534	-	-	HYPH	I-NP
O	534	546	inflammatory	inflammatory	JJ	I-NP
O	547	548	[	[	(	I-NP
O	548	549	5	5	CD	I-NP
O	549	550	]	]	)	O
O	550	551	,	,	,	O
O	552	568	atheroprotective	atheroprotective	JJ	B-ADJP
O	569	570	[	[	(	O
O	570	571	6	6	CD	B-NP
O	571	572	]	]	)	O
O	572	573	,	,	,	O
O	574	577	and	and	CC	O
O	578	590	antidiabetic	antidiabetic	JJ	B-NP
O	591	592	[	[	(	I-NP
O	592	593	7	7	CD	I-NP
O	593	594	]	]	)	I-NP
O	595	602	effects	effect	NNS	I-NP
O	602	603	.	.	.	O

O	604	610	Recent	Recent	JJ	B-NP
O	611	619	findings	finding	NNS	I-NP
O	620	627	suggest	suggest	VBP	B-VP
O	628	632	that	that	IN	B-SBAR
O	633	644	adiponectin	adiponectin	NN	B-NP
O	645	648	may	may	MD	B-VP
O	649	651	be	be	VB	I-VP
O	652	660	involved	involve	VBN	I-VP
O	661	663	in	in	IN	B-PP
O	664	667	the	the	DT	B-NP
O	668	680	pathogenesis	pathogenesis	NN	I-NP
O	681	683	of	of	IN	B-PP
O	684	694	rheumatoid	rheumatoid	JJ	B-NP
O	695	704	arthritis	arthritis	NN	I-NP
O	705	706	(	(	(	O
O	706	708	RA	RA	NN	B-NP
O	708	709	)	)	)	O
O	709	710	.	.	.	O

O	711	717	Levels	Level	NNS	B-NP
O	718	720	of	of	IN	B-PP
O	721	732	adiponectin	adiponectin	NN	B-NP
O	733	735	in	in	IN	B-PP
B-Organism_substance	736	744	synovial	synovial	JJ	B-NP
I-Organism_substance	745	750	fluid	fluid	NN	I-NP
O	751	754	and	and	CC	I-NP
B-Organism_substance	755	759	sera	serum	NNS	I-NP
O	760	764	were	be	VBD	B-VP
O	765	773	elevated	elevate	VBN	I-VP
O	774	776	in	in	IN	B-PP
O	777	785	patients	patient	NNS	B-NP
O	786	790	with	with	IN	B-PP
O	791	793	RA	RA	NN	B-NP
O	794	795	[	[	(	O
O	795	796	8	8	CD	B-NP
O	796	797	,	,	,	I-NP
O	797	798	9	9	CD	I-NP
O	798	799	]	]	)	O
O	799	800	.	.	.	O

O	801	812	Adiponectin	Adiponectin	NN	B-NP
O	813	817	also	also	RB	B-ADVP
O	818	825	induces	induce	VBZ	B-VP
O	826	829	the	the	DT	B-NP
O	830	840	production	production	NN	I-NP
O	841	843	of	of	IN	B-PP
O	844	859	proinflammatory	proinflammatory	JJ	B-NP
O	860	869	cytokines	cytokine	NNS	I-NP
O	869	870	,	,	,	O
O	871	873	IL	IL	NN	B-NP
O	873	874	-	-	HYPH	O
O	874	875	6	6	CD	B-NP
O	875	876	,	,	,	O
O	877	883	matrix	matrix	NN	B-NP
O	884	901	metalloproteinase	metalloproteinase	NN	I-NP
O	902	903	(	(	(	O
O	903	906	MMP	MMP	NN	B-NP
O	906	907	)	)	)	O
O	907	908	-	-	HYPH	B-NP
O	908	909	1	1	CD	I-NP
O	909	910	,	,	,	O
O	911	914	and	and	CC	O
O	915	917	IL	IL	NN	B-NP
O	917	918	-	-	HYPH	O
O	918	919	8	8	CD	B-NP
O	920	924	from	from	IN	B-PP
O	925	927	RA	RA	NN	B-NP
B-Cell	928	936	synovial	synovial	JJ	I-NP
I-Cell	937	948	fibroblasts	fibroblast	NNS	I-NP
O	949	951	in	in	FW	B-NP
O	952	957	vitro	vitro	FW	I-NP
O	958	959	[	[	(	I-NP
O	959	961	10	10	CD	I-NP
O	961	962	,	,	,	I-NP
O	962	964	11	11	CD	I-NP
O	964	965	]	]	)	O
O	965	966	.	.	.	O

O	967	971	Thus	Thus	RB	B-ADVP
O	971	972	,	,	,	O
O	973	975	it	it	PRP	B-NP
O	976	979	was	be	VBD	B-VP
O	980	989	suggested	suggest	VBN	I-VP
O	990	994	that	that	IN	B-SBAR
O	995	1006	adiponectin	adiponectin	NN	B-NP
O	1007	1010	can	can	MD	B-VP
O	1011	1015	also	also	RB	I-VP
O	1016	1021	exert	exert	VB	I-VP
O	1022	1033	significant	significant	JJ	B-NP
O	1034	1049	proinflammatory	proinflammatory	JJ	I-NP
O	1050	1053	and	and	CC	I-NP
O	1054	1060	matrix	matrix	NN	I-NP
O	1060	1061	-	-	HYPH	O
O	1061	1070	degrading	degrade	VBG	B-VP
O	1071	1078	effects	effect	NNS	B-NP
O	1078	1079	.	.	.	O

O	1080	1087	However	However	RB	B-ADVP
O	1087	1088	,	,	,	O
O	1089	1092	the	the	DT	B-NP
O	1093	1097	role	role	NN	I-NP
O	1098	1100	of	of	IN	B-PP
O	1101	1112	adiponectin	adiponectin	NN	B-NP
O	1113	1115	in	in	IN	B-PP
O	1116	1119	the	the	DT	B-NP
O	1120	1132	pathogenesis	pathogenesis	NN	I-NP
O	1133	1135	of	of	IN	B-PP
O	1136	1138	RA	RA	NN	B-NP
O	1139	1141	is	be	VBZ	B-VP
O	1142	1147	still	still	RB	B-ADVP
O	1148	1161	controversial	controversial	JJ	B-ADJP
O	1162	1169	because	because	IN	B-PP
O	1170	1172	of	of	IN	I-PP
O	1173	1184	conflicting	conflict	VBG	B-VP
O	1185	1192	reports	report	NNS	B-NP
O	1193	1198	about	about	IN	B-PP
O	1199	1202	its	its	PRP$	B-NP
O	1203	1211	function	function	NN	I-NP
O	1212	1213	[	[	(	I-NP
O	1213	1215	10	10	CD	I-NP
O	1215	1216	,	,	,	I-NP
O	1216	1218	12	12	CD	I-NP
O	1218	1219	-	-	HYPH	I-NP
O	1219	1221	15	15	CD	I-NP
O	1221	1222	]	]	)	O
O	1222	1223	.	.	.	O

O	1224	1226	In	In	IN	B-PP
O	1227	1237	particular	particular	JJ	B-NP
O	1237	1238	,	,	,	O
O	1239	1250	adiponectin	adiponectin	NN	B-NP
O	1251	1256	seems	seem	VBZ	B-VP
O	1257	1259	to	to	TO	I-VP
O	1260	1264	play	play	VB	I-VP
O	1265	1267	an	an	DT	B-NP
O	1268	1272	anti	anti	AFX	I-NP
O	1272	1273	-	-	HYPH	I-NP
O	1273	1285	inflammatory	inflammatory	JJ	I-NP
O	1286	1290	role	role	NN	I-NP
O	1291	1298	because	because	IN	B-SBAR
O	1299	1301	it	it	PRP	B-NP
O	1302	1315	significantly	significantly	RB	B-ADVP
O	1316	1325	inhibited	inhibit	VBD	B-VP
O	1326	1328	IL	IL	NN	B-NP
O	1328	1329	-	-	HYPH	B-NP
O	1329	1334	1beta	1beta	NN	I-NP
O	1334	1335	-	-	HYPH	B-VP
O	1335	1345	stimulated	stimulate	VBN	B-NP
B-Cell	1346	1354	synovial	synovial	JJ	I-NP
I-Cell	1355	1359	cell	cell	NN	I-NP
O	1360	1373	proliferation	proliferation	NN	I-NP
O	1374	1376	in	in	IN	B-PP
O	1377	1385	collagen	collagen	NN	B-NP
O	1385	1386	-	-	HYPH	B-NP
O	1386	1393	induced	induce	VBN	I-NP
O	1394	1403	arthritic	arthritic	JJ	I-NP
O	1404	1408	mice	mouse	NNS	I-NP
O	1408	1409	,	,	,	O
O	1410	1417	despite	despite	IN	B-PP
O	1418	1427	increased	increase	VBN	B-NP
O	1428	1430	IL	IL	NN	I-NP
O	1430	1431	-	-	HYPH	O
O	1431	1432	6	6	CD	B-NP
O	1433	1443	expression	expression	NN	I-NP
O	1444	1445	[	[	(	O
O	1445	1447	16	16	CD	B-NP
O	1447	1448	]	]	)	O
O	1448	1449	.	.	.	O

O	1450	1452	In	In	IN	B-PP
O	1453	1461	contrast	contrast	NN	B-NP
O	1461	1462	,	,	,	O
O	1463	1467	high	high	JJ	B-NP
O	1467	1468	-	-	HYPH	I-NP
O	1468	1473	grade	grade	NN	I-NP
O	1474	1486	inflammation	inflammation	NN	I-NP
O	1487	1489	in	in	IN	B-PP
O	1490	1492	RA	RA	NN	B-NP
O	1493	1501	patients	patient	NNS	I-NP
O	1502	1505	was	be	VBD	B-VP
O	1506	1516	negatively	negatively	RB	I-VP
O	1517	1527	correlated	correlate	VBN	I-VP
O	1528	1532	with	with	IN	B-PP
O	1533	1544	circulating	circulate	VBG	B-VP
O	1545	1556	adiponectin	adiponectin	NN	B-NP
O	1557	1571	concentrations	concentration	NNS	I-NP
O	1572	1573	[	[	(	O
O	1573	1575	17	17	CD	B-NP
O	1575	1576	]	]	)	O
O	1576	1577	.	.	.	O

O	1578	1584	Rather	Rather	RB	B-ADVP
O	1584	1585	,	,	,	O
O	1586	1588	it	it	PRP	B-NP
O	1589	1592	was	be	VBD	B-VP
O	1593	1602	suggested	suggest	VBN	I-VP
O	1603	1607	that	that	IN	B-SBAR
O	1608	1619	circulating	circulate	VBG	B-VP
O	1620	1631	adiponectin	adiponectin	NN	B-NP
O	1632	1635	may	may	MD	B-VP
O	1636	1638	be	be	VB	I-VP
O	1639	1647	involved	involve	VBN	I-VP
O	1648	1650	in	in	IN	B-PP
B-Anatomical_system	1651	1665	cardiovascular	cardiovascular	JJ	B-NP
O	1666	1673	disease	disease	NN	I-NP
O	1674	1676	in	in	IN	B-PP
O	1677	1679	RA	RA	NN	B-NP
O	1680	1688	patients	patient	NNS	I-NP
O	1688	1689	.	.	.	O

O	1690	1698	Although	Although	IN	B-SBAR
O	1699	1703	this	this	DT	B-NP
O	1704	1717	contradiction	contradiction	NN	I-NP
O	1718	1721	was	be	VBD	B-VP
O	1722	1728	partly	partly	RB	I-VP
O	1729	1738	explained	explain	VBN	I-VP
O	1739	1741	by	by	IN	B-PP
O	1742	1745	the	the	DT	B-NP
O	1746	1755	induction	induction	NN	I-NP
O	1756	1758	of	of	IN	B-PP
O	1759	1768	tolerance	tolerance	NN	B-NP
O	1769	1771	to	to	TO	B-PP
O	1772	1784	inflammatory	inflammatory	JJ	B-NP
O	1785	1792	stimuli	stimulus	NNS	I-NP
O	1793	1795	by	by	IN	B-PP
O	1796	1807	adiponectin	adiponectin	NN	B-NP
O	1808	1809	[	[	(	O
O	1809	1811	18	18	CD	B-NP
O	1811	1812	]	]	)	O
O	1812	1813	,	,	,	O
O	1814	1817	the	the	DT	B-NP
O	1818	1821	pro	pro	AFX	I-NP
O	1821	1822	-	-	HYPH	I-NP
O	1823	1825	or	or	CC	I-NP
O	1826	1830	anti	anti	AFX	I-NP
O	1830	1831	-	-	HYPH	I-NP
O	1831	1843	inflammatory	inflammatory	JJ	I-NP
O	1844	1851	effects	effect	NNS	I-NP
O	1852	1854	of	of	IN	B-PP
O	1855	1866	adiponectin	adiponectin	NN	B-NP
O	1867	1869	on	on	IN	B-PP
O	1870	1873	the	the	DT	B-NP
O	1874	1886	pathogenesis	pathogenesis	NN	I-NP
O	1887	1889	of	of	IN	B-PP
O	1890	1892	RA	RA	NN	B-NP
O	1893	1899	remain	remain	VBP	B-VP
O	1900	1907	unknown	unknown	JJ	B-ADJP
O	1907	1908	.	.	.	O

O	1909	1913	With	With	IN	B-PP
O	1914	1920	regard	regard	NN	B-NP
O	1921	1923	to	to	TO	B-PP
O	1924	1935	adiponectin	adiponectin	NN	B-NP
O	1935	1936	'	'	''	O
O	1936	1937	s	s	VBZ	B-VP
O	1938	1953	proinflammatory	proinflammatory	JJ	B-NP
O	1954	1961	effects	effect	NNS	I-NP
O	1961	1962	,	,	,	O
O	1963	1965	we	we	PRP	B-NP
O	1966	1974	wondered	wonder	VBD	B-VP
O	1975	1982	whether	whether	IN	B-SBAR
O	1983	1994	adiponectin	adiponectin	NN	B-NP
O	1995	2000	might	might	MD	B-VP
O	2001	2010	stimulate	stimulate	VB	I-VP
O	2011	2014	the	the	DT	B-NP
O	2015	2025	production	production	NN	I-NP
O	2026	2028	of	of	IN	B-PP
O	2029	2037	vascular	vascular	JJ	B-NP
O	2038	2049	endothelial	endothelial	JJ	I-NP
O	2050	2056	growth	growth	NN	I-NP
O	2057	2063	factor	factor	NN	I-NP
O	2064	2065	(	(	(	O
O	2065	2069	VEGF	VEGF	NN	B-NP
O	2069	2070	)	)	)	O
O	2071	2074	and	and	CC	O
O	2075	2079	MMPs	MMP	NNS	B-NP
O	2080	2082	as	as	RB	B-CONJP
O	2083	2087	well	well	RB	I-CONJP
O	2088	2090	as	as	IN	I-CONJP
O	2091	2106	proinflammatory	proinflammatory	JJ	B-NP
O	2107	2116	mediators	mediator	NNS	I-NP
O	2117	2121	like	like	IN	B-PP
O	2122	2124	IL	IL	NN	B-NP
O	2124	2125	-	-	HYPH	B-NP
O	2125	2130	1beta	1beta	NN	I-NP
O	2131	2134	and	and	CC	I-NP
O	2135	2138	TNF	TNF	NN	I-NP
O	2138	2139	-	-	HYPH	O
O	2139	2144	alpha	alpha	SYM	B-NP
O	2145	2147	do	do	NN	I-NP
O	2147	2148	.	.	.	O

O	2149	2151	In	In	IN	B-PP
O	2152	2156	this	this	DT	B-NP
O	2157	2162	study	study	NN	I-NP
O	2162	2163	,	,	,	O
O	2164	2166	we	we	PRP	B-NP
O	2167	2179	investigated	investigate	VBD	B-VP
O	2180	2183	the	the	DT	B-NP
O	2184	2195	stimulatory	stimulatory	JJ	I-NP
O	2196	2202	effect	effect	NN	I-NP
O	2203	2205	of	of	IN	B-PP
O	2206	2217	adiponectin	adiponectin	NN	B-NP
O	2218	2220	on	on	IN	B-PP
O	2221	2224	the	the	DT	B-NP
O	2225	2235	production	production	NN	I-NP
O	2236	2238	of	of	IN	B-PP
O	2239	2241	IL	IL	NN	B-NP
O	2241	2242	-	-	HYPH	O
O	2242	2243	6	6	CD	B-NP
O	2243	2244	,	,	,	O
O	2245	2247	IL	IL	NN	B-NP
O	2247	2248	-	-	HYPH	O
O	2248	2249	8	8	CD	B-NP
O	2249	2250	,	,	,	O
O	2251	2264	prostaglandin	prostaglandin	NN	B-NP
O	2265	2267	E2	E2	NN	I-NP
O	2268	2269	(	(	(	O
O	2269	2273	PGE2	PGE2	NN	B-NP
O	2273	2274	)	)	)	O
O	2274	2275	,	,	,	O
O	2276	2280	VEGF	VEGF	NN	B-NP
O	2280	2281	,	,	,	O
O	2282	2285	and	and	CC	O
O	2286	2290	MMPs	MMP	NNS	B-NP
O	2290	2291	.	.	.	O

O	2292	2294	In	In	IN	B-PP
O	2295	2303	addition	addition	NN	B-NP
O	2303	2304	,	,	,	O
O	2305	2308	the	the	DT	B-NP
O	2309	2320	correlation	correlation	NN	I-NP
O	2321	2328	between	between	IN	B-PP
O	2329	2340	adiponectin	adiponectin	NN	B-NP
O	2341	2344	and	and	CC	I-NP
O	2345	2349	VEGF	VEGF	NN	I-NP
O	2350	2352	or	or	CC	I-NP
O	2353	2357	MMPs	MMP	NNS	I-NP
O	2358	2361	was	be	VBD	B-VP
O	2362	2374	investigated	investigate	VBN	I-VP
O	2375	2377	by	by	IN	B-PP
O	2378	2387	measuring	measure	VBG	B-VP
O	2388	2391	the	the	DT	B-NP
O	2392	2398	levels	level	NNS	I-NP
O	2399	2401	of	of	IN	B-PP
O	2402	2407	these	these	DT	B-NP
O	2408	2413	three	three	CD	I-NP
O	2414	2422	proteins	protein	NNS	I-NP
O	2423	2425	in	in	IN	B-PP
O	2426	2429	the	the	DT	B-NP
B-Organism_substance	2430	2435	joint	joint	JJ	I-NP
I-Organism_substance	2436	2441	fluid	fluid	NN	I-NP
O	2442	2444	of	of	IN	B-PP
O	2445	2453	patients	patient	NNS	B-NP
O	2454	2458	with	with	IN	B-PP
O	2459	2461	RA	RA	NN	B-NP
O	2462	2464	or	or	CC	O
O	2465	2479	osteoarthritis	osteoarthritis	NN	B-NP
O	2480	2481	(	(	(	O
O	2481	2483	OA	OA	NN	B-NP
O	2483	2484	)	)	)	O
O	2484	2485	.	.	.	O

